Liver transplantation in the setting of chronic HCV

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 531-548

  Terrault, Norah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholestatic hepatitis; Donor age; Elastography; IL28B; Liver biopsy; Peginterferon; Protease inhibitors; Recurrent cirrhosis; Ribavirin

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BOCEPREVIR; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLATASVIR; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORFLOXACIN; PEGINTERFERON; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

ACUTE GRAFT REJECTION; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE HEPATITIS; BACTEREMIA; BACTERIAL PERITONITIS; CHOLESTATIC HEPATITIS; CHRONIC GRAFT REJECTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; ELASTOGRAPHY; GENE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IL28B GENE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA;

AGE FACTORS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROTEASE INHIBITORS; RECURRENCE; RIBAVIRIN; RISK FACTORS; TISSUE DONORS;

EID: 84870397497     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.010     Document Type: Article

References (100)

1. W.R. Kim, N.A. Terrault, R.A. Pedersen, T.M. Therneau, E. Edwards, and A.A. Hindman Trends in waiting list registration for liver transplantation for viral hepatitis in the United States Gastroenterology 137 2009 1680 1686
2. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
3. B.J. Veldt, J.J. Poterucha, K.D. Watt, R.H. Wiesner, J.E. Hay, and W.K. Kremers Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection Am J Transplant 8 2008 2426 2433
4. M. Berenguer, A. Palau, V. Aguilera, J.M. Rayon, F.S. Juan, and M. Prieto Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679 687
5. N.A. Terrault, and M. Berenguer Treating hepatitis C infection in liver transplant recipients Liver Transplant 12 2006 1192 1204
6. T.D. Schiano, J.A. Gutierrez, J.L. Walewski, M.I. Fiel, B. Cheng, and H. Bodenheimer Jr. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors Hepatology 42 2005 1420 1428
7. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, and M. Navasa Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
8. N. Yilmaz, M.L. Shiffman, R.T. Stravitz, R.K. Sterling, V.A. Luketic, and A.J. Sanyal A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation Liver Transplant 13 2007 975 983
9. J.A. Carrion, F. Torres, G. Crespo, R. Miquel, J.C. Garcia-Valdecasas, and M. Navasa Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation Hepatology 51 2010 23 34
10. U. Neumann, T. Berg, M. Bahra, D. Seehofer, J. Langrehr, and R. Neuhaus Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
11. P. Bacchetti, R.D. Boylan, N.A. Terrault, A. Monto, and M. Berenguer Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant Int J Biostat 6 2010 Article7
12. M. Berenguer, L. Ferrell, J. Watson, M. Prieto, M. Kim, and M. Rayon HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 2000 673 684
13. R. Firpi, V. Clark, C. Soldevila-Pico, G. Morelli, R. Cabrera, and C. Levy The natural history of hepatitis C cirrhosis after liver transplantation Liver Transplant 15 2009 1063 1071
14. R. Valadao, J. Lai, E. Verna, J. O'Leary, L. Forman, and R. Stravitz Racial/ethnic differences in survival and predictors of death among liver transplant (LT) with advanced fibrosis (AF) from hepatitis C virus (HCV) Am J Transplant 12 supp 3 2012 A198
15. M. Berenguer, M. Prieto, J.M. Rayon, J. Mora, M. Pastor, and V. Ortiz Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852 858
16. S.A. Taga, M.K. Washington, N. Terrault, T.L. Wright, K.A. Somberg, and L.D. Ferrell Cholestatic hepatitis C in liver allografts Liver Transplant Surg 4 1998 304 310
17. J.C. Lai, E.C. Verna, R.S. Brown Jr., J.G. O'Leary, J.F. Trotter, and L.M. Forman Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men Hepatology 54 2011 418 424
18. P. Thuluvath, M. Guidinger, J. Fung, L. Johnson, S. Rayhill, and S. Pelletier Liver transplantation in the United States, 1999-2008 Am J Transplant 10 2010 1003 1019
19. V. Saxena, J.C. Lai, J.G. O'Leary, E.C. Verna, R.S. Brown Jr., and R.T. Stravitz Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C Liver Transplant 18 2012 524 531
20. J.E. Layden, S. Cotler, K.A. Brown, M.R. Lucey, H.S. Te, and S. Eswaran Racial differences in fibrosis progression after HCV-related liver transplantation Transplantation 94 2012 178 184
21. N.A. Terrault, M.E. Roland, T. Schiano, L. Dove, M.T. Wong, and F. Poordad Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection Liver Transplant 18 2012 716 726
22. J.M. Miro, M. Montejo, L. Castells, A. Rafecas, S. Moreno, and F. Aguero Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study Am J Transplant 12 2012 1866 1876
23. I.W. Graziadei, H.M. Zoller, A. Schloegl, K. Nachbaur, K.P. Pfeiffer, and W. Mark Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation Liver Transplant 18 2012 671 679
24. M.R. Charlton, A. Thompson, B.J. Veldt, K. Watt, H. Tillmann, and J.J. Poterucha Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection Hepatology 53 2011 317 324
25. C.M. Lange, D. Moradpour, A. Doehring, H.A. Lehr, B. Mullhaupt, and S. Bibert Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection J Hepatol 55 2011 322 327
26. A. Duarte-Rojo, B.J. Veldt, D.D. Goldstein, H.L. Tillman, K.D. Watt, and J.K. Heimbach The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables Transplantation 94 2012 197 203
27. M. Berenguer, J. Crippin, R. Gish, N. Bass, A. Bostrom, and G. Netto A model to predict severe HCV-related disease following liver transplantation Hepatology 38 2003 34 41
28. K.W. Burak, W.K. Kremers, K.P. Batts, R.H. Wiesner, C.B. Rosen, and R.R. Razonable Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C Liver Transplant 8 2002 362 369
29. J.R. Lake, J.S. Shorr, B.J. Steffen, A.H. Chu, R.D. Gordon, and R.H. Wiesner Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis Am J Transplant 5 2005 549 557
30. F. Durand, J.F. Renz, B. Alkofer, P. Burra, P.A. Clavien, and R.J. Porte Report of the Paris consensus meeting on expanded criteria donors in liver transplantation Liver Transplant 14 2008 1694 1707
31. J.C. Lai, J.G. O'Leary, J.F. Trotter, E.C. Verna, R.S. Brown Jr., and R.T. Stravitz Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study Liver Transplant 18 2012 532 538
32. R. Ballarin, A. Cucchetti, M. Spaggiari, R. Montalti, F. Di Benedetto, and S. Nadalin Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study Transplantation 91 2011 1265 1272
33. V.I. Machicao, M. Krishna, H. Bonatti, B.A. Aqel, J.H. Nguyen, and S.D. Weigand Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation Liver Transplant 10 2004 599 606
34. J. Briceno, R. Ciria, M. Pleguezuelo, M. de la Mata, J. Muntane, and A. Naranjo Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis Liver Transplant 15 2009 37 48
35. T. Uemura, V. Ramprasad, C.S. Hollenbeak, D. Bezinover, and Z. Kadry Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data Am J Transplant 12 2012 984 991
36. C.B. Taner, I.G. Bulatao, A.P. Keaveny, D.L. Willingham, S. Pungpapong, and D.K. Perry Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus Liver Transplant 17 2011 641 649
37. R. Tao, K. Ruppert, R.J. Cruz Jr., S.M. Malik, O. Shaikh, and J. Ahmad Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts Liver Transplant 16 2010 1288 1295
38. N.A. Terrault, M.L. Shiffman, A.S. Lok, S. Saab, L. Tong, and R.S. Brown Jr. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation Liver Transplant 13 2007 122 129
39. W. Bosch, M.G. Heckman, S. Pungpapong, N.N. Diehl, J.A. Shalev, and W.C. Hellinger Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation Transplantation 93 2012 723 728
40. K.B. Chopra, A.J. Demetris, K. Blakolmer, I. Dvorchik, T. Laskus, and L.F. Wang Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation Transplantation 76 2003 1487 1491
41. M. Prieto, M. Berenguer, J. Rayon, J. Cordoba, L. Arguello, and D. Carrasco High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250 256
42. G.B. Klintmalm, W.K. Washburn, S.M. Rudich, T.G. Heffron, L.W. Teperman, and C. Fasola Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study Liver Transplant 13 2007 1521 1531
43. K. Watt, R. Dierkhising, J. Heimbach, and M. Charlton Impact of sirolimus and tacrolimus on mortality & graft loss in liver transplant recipients with and without HCV - an analysis of the SRTR database Liver Transplant 18 2012 1029 1036
44. R.H. Wiesner, B.J. Steffen, K.M. David, A.H. Chu, R.D. Gordon, and J.R. Lake Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients Am J Transplant 6 2006 1609 1616
45. R.S. Mangus, J.A. Fridell, R.M. Vianna, P.Y. Kwo, J. Chen, and A.J. Tector Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up Liver Transplant 18 2012 786 795
46. B.J. Veldt, J.J. Poterucha, K.D. Watt, R.H. Wiesner, J.E. Hay, and C.B. Rosen Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C Am J Transplant 9 2009 1406 1413
47. D. Brandman, A. Pingitore, J. Lai, J. Roberts, L. Ferrell, and N. Bass Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus Liver Transplant 17 2011 1380 1386
48. R. Wiesner, M. Sorrell, F. Villamil International Liver Transplantation Society Expert Panel Report of the first International liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C Liver Transplant 9 2003 S1 S9
49. A. Demetris Evolution of hepatitis C virus in liver allografts Liver Transplant 51 2009 S35 S41
50. B. Roche, M. Sebagh, M.L. Canfora, T. Antonini, A.M. Roque-Afonso, and V. Delvart Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis Liver Transplant 14 2008 1766 1777
51. H. Lim, G. Lau, G. Davis, D. Dolson, and J. Lau Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection Gastroenterology 106 1994 248 251
52. T.K. Narang, W. Ahrens, and M.W. Russo Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria Liver Transplant 16 2010 1228 1235
53. M. Fiel, K. Agarwal, C. Stanca, N. Elhajj, N. Kontorinis, and S. Thung Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus Liver Transplant 14 2008 861 871
54. S. Berardi, F. Lodato, A. Gramenzi, A. D'Errico, M. Lenzi, and A. Bontadini High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 56 2007 237 242
55. C.O. Adebajo, J.A. Talwalkar, J.J. Poterucha, W.R. Kim, and M.R. Charlton Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis Liver Transplant 18 2012 323 331
56. E. Cholongitas, E. Tsochatzis, J. Goulis, and A.K. Burroughs Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review Transplant International 23 2010 861 870
57. J.A. Carrion, M. Navasa, J. Bosch, M. Bruguera, R. Gilabert, and X. Forns Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation Liver Transplant 12 2006 1791 1798
58. A. Blasco, X. Forns, J. Carrión, J. García-Pagán, R. Gilabert, and A. Rimola Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation Hepatology 43 2006 492 499
59. J. Carrion, G. Fernandez-Varo, M. Bruguera, J. GarcÌa-Pagan, J. GarcÌa-Valdecasas, and S. Perez-del-Pulgar Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation Gastroenterology 138 2010 147 158
60. S. Pungpapong, D.P. Nunes, M. Krishna, R. Nakhleh, K. Chambers, and M. Ghabril Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C Liver Transplant 14 2008 1294 1302
61. N.A. Terrault Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation Liver Transplant 9 2003 S95 S100
62. N. Bzowej, D.R. Nelson, N.A. Terrault, G.T. Everson, L.L. Teng, and A. Prabhakar PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus Liver Transplant 17 2011 528 538
63. F. Tekin, F. Gunsar, Z. Karasu, U. Akarca, and G. Ersoz Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics Aliment Pharmacol Ther 27 2008 1081 1085
64. G.T. Everson, J. Trotter, L. Forman, M. Kugelmas, A. Halprin, and B. Fey Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255 262
65. H. Massoumi, H. Elsiesy, V. Khaitova, B. Peterson, E. Norkus, and P. Grewal An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant Transplantation 88 2009 729 735
66. J.A. Carrion, E. Martinez-Bauer, G. Crespo, S. Ramirez, S. Perez-del-Pulgar, and J.C. Garcia-Valdecasas Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study J Hepatol 50 2009 719 728
67. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown Jr RS, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology, in press.
68. A. Iacobellis, M. Siciliano, F. Perri, B.E. Annicchiarico, G. Leandro, and N. Caruso Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study J Hepatol 46 2007 206 212
69. C. Hezode, C. Dorival, F. Zoulim, V. de Ledinghen, T. Poynard, P. Mathurin The CUPIC study group Real-life safety of telaprevir and boceprevir combination with peginterferon alfa/ribavirin, in cirrhotic non responders. Results of the French early access program J Hepatol 56 S2 2012 A8
70. J.A. Carrion, M. Navasa, M. Garcia-Retortillo, J.C. Garcia-Pagan, G. Crespo, and M. Bruguera Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study Gastroenterology 132 2007 1746 1756
71. R. Firpi, M. Abdelmalek, C. Soldevila-Pico, A. Reed, A. Hemming, and R. Howard Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C Liver Transplant 8 2002 1000 1006
72. E. Xirouchakis, C. Triantos, P. Manousou, A. Sigalas, V. Calvaruso, and A. Corbani Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies J Viral Hepat 15 2008 699 709
73. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
74. C.S. Wang, H.H. Ko, E.M. Yoshida, C.A. Marra, and K. Richardson Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis Am J Transplant 6 2006 1586 1599
75. T. Fukuhara, A. Taketomi, T. Motomura, S. Okano, A. Ninomiya, and T. Abe Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C Gastroenterology 139 2010 1577 1585 1585 e1-3
76. M. Coto-Llerena, S. Perez-Del-Pulgar, G. Crespo, J.A. Carrion, S.M. Martinez, and J.M. Sanchez-Tapias Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation Am J Transplant 11 2011 1051 1057
77. T. Kawaoka, S. Takahashi, S. Takaki, A. Hiramatsu, K. Waki, and N. Hiraga IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation J Gastroenterol Hepatol 27 2012 1467 1472
78. E. Oton, R. Barcena, J.M. Moreno-Planas, V. Cuervas-Mons, A. Moreno-Zamora, and C. Barrios Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin Am J Transplant 6 2006 2348 2355
79. F.D. Gordon, P. Kwo, R. Ghalib, J. Crippin, H.E. Vargas, and K.A. Brown Peginterferon-alpha-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation J Clin Gastroenterol 46 2012 700 708
80. M. Berenguer, M. Prieto, A. Palau, D. Carrasco, J.M. Rayon, and F. Calvo Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy Eur J Gastroenterol Hepatol 16 2004 1207-2
81. T. Bizollon, P. Pradat, J.Y. Mabrut, S. Radenne, C. Ducerf, and J. Baulieux Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation Am J Transplant 7 2007 448 453
82. J. Flemming, J. Zipperstein, K.-Y. Jen, M.G. Peters, J. Roberts, and N. Terrault Histologic response to anti-viral therapy confers a mortality benefit in virologic non-responders after liver transplantation Liver Transplant 18 S1 2012 LB2
83. V.R. Bertuzzo, M. Cescon, M.C. Morelli, P. Di Gioia, M. Tame, and S. Lorenzini Long-term antiviral treatment for recurrent hepatitis C after liver transplantation Dig Liver Dis 44 2012 861 867
84. E. Hulskotte, S. Gupta, F. Xuan, M. van Zutven, E. O'Mara, and H.P. Feng Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers Hepatology 56 2012 1622 1630
85. V. Garg, R. van Heeswijk, J.E. Lee, K. Alves, P. Nadkarni, and X. Luo Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
86. J.J. Kiser, J.R. Burton, P.L. Anderson, and G.T. Everson Review and management of drug interactions with boceprevir and telaprevir Hepatology 55 2012 1620 1628
87. A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy, and G. Pageaux Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience J Hepatol 56 S2 2012 A47
88. M. Martinez, S. Mukherjee, F. Rochling, D. Schafer, and M. Sorrell Early experience with triple therapy in patients on cyclosporine A for hepatitis C recurrence after liver transplantation Liver Transplant 18 2012 Abstract LB01
89. R.J. Fontana, E.A. Hughes, H. Appelman, R. Hindes, D. Dimitrova, and M. Bifano A case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis c following liver retransplantation Liver Transplant 18 2012 1053 1059
90. J. Levitsky, M.I. Fiel, J.P. Norvell, E. Wang, K.D. Watt, and M.P. Curry Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon Gastroenterology 142 2012 1132 1139 e1
91. M. Kugelmas, M.J. Osgood, J.F. Trotter, T. Bak, M. Wachs, and L. Forman Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection Liver Transplant 9 2003 1159 1165
92. F.Y. Yao, S. Saab, N.M. Bass, R. Hirose, D. Ly, and N. Terrault Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores Hepatology 39 2004 230 238
93. J.A. Carrion, M. Navasa, and X. Forns Retransplantation in patients with hepatitis C recurrence after liver transplantation J Hepatol 53 2010 962 970
94. H.R. Rosen, M. Prieto, T. Casanovas-Taltavull, V. Cuervas-Mons, O. Guckelberger, and P. Muiesan Validation and refinement of survival models for liver retransplantation Hepatology 38 2003 460 469
95. M. Ghabril, R. Dickson, and R. Wiesner Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection Am J Transplant 8 2008 404 411
96. T. McCashland, K. Watt, E. Lyden, L. Adams, M. Charlton, and A.D. Smith Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study Liver Transplant 13 2007 1246 1253
97. A. Andres, E. Gerstel, C. Combescure, S. Asthana, S. Merani, and P. Majno A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis Transplantation 93 2012 717 722
98. M.M. Linhares, D. Azoulay, D. Matos, A. Castelo-Filho, T. Trivino, and A. Goldenberg Liver retransplantation: a model for determining long-term survival Transplantation 81 2006 1016 1021
99. P.G. Northup, T.L. Pruett, D.M. Kashmer, C.K. Argo, C.L. Berg, and T.M. Schmitt Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index Am J Transplant 7 2007 1984 1988
100. J.F. Gallegos-Orozco, A. Yosephy, B. Noble, B.A. Aqel, T.J. Byrne, and E.J. Carey Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course Liver Transplant 15 2009 1872 1881